Coastwise Capital Group LLC reduced its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 1.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 6,330 shares of the company’s stock after selling 72 shares during the quarter. Coastwise Capital Group LLC’s holdings in Johnson & Johnson were worth $915,000 as of its most recent filing with the SEC.
Other institutional investors also recently modified their holdings of the company. International Assets Investment Management LLC lifted its position in shares of Johnson & Johnson by 20,130.0% during the 3rd quarter. International Assets Investment Management LLC now owns 3,454,473 shares of the company’s stock valued at $559,832,000 after acquiring an additional 3,437,397 shares during the period. Janus Henderson Group PLC lifted its position in shares of Johnson & Johnson by 228.1% during the 3rd quarter. Janus Henderson Group PLC now owns 3,389,361 shares of the company’s stock valued at $549,223,000 after acquiring an additional 2,356,359 shares during the period. Franklin Resources Inc. lifted its position in shares of Johnson & Johnson by 11.4% during the 3rd quarter. Franklin Resources Inc. now owns 16,840,069 shares of the company’s stock valued at $2,721,355,000 after acquiring an additional 1,729,281 shares during the period. Holocene Advisors LP acquired a new position in shares of Johnson & Johnson during the 3rd quarter valued at $225,040,000. Finally, FMR LLC lifted its position in shares of Johnson & Johnson by 7.4% during the 3rd quarter. FMR LLC now owns 18,316,920 shares of the company’s stock valued at $2,968,440,000 after acquiring an additional 1,265,748 shares during the period. 69.55% of the stock is owned by institutional investors.
Johnson & Johnson Price Performance
Shares of NYSE JNJ opened at $151.82 on Tuesday. The stock has a fifty day simple moving average of $147.61 and a two-hundred day simple moving average of $156.12. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85. The firm has a market cap of $365.53 billion, a price-to-earnings ratio of 22.83, a price-to-earnings-growth ratio of 2.44 and a beta of 0.52. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45.
Johnson & Johnson Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.27%. Johnson & Johnson’s dividend payout ratio is currently 74.59%.
Insiders Place Their Bets
In other Johnson & Johnson news, Director Mark A. Weinberger acquired 1,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the transaction, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. This represents a ? increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.16% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of research analysts recently issued reports on JNJ shares. Guggenheim boosted their target price on shares of Johnson & Johnson from $162.00 to $166.00 and gave the company a “neutral” rating in a research report on Monday. Wolfe Research assumed coverage on shares of Johnson & Johnson in a report on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price on the stock. Leerink Partners cut their price target on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Morgan Stanley cut their price target on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Finally, Raymond James cut their price target on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $170.67.
Check Out Our Latest Report on Johnson & Johnson
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Recommended Stories
- Five stocks we like better than Johnson & Johnson
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- How to Invest in Small Cap Stocks
- When to Sell a Stock for Profit or Loss
- These Are the Dividend Stocks Insiders Bought in January
- Health Care Stocks Explained: Why You Might Want to Invest
- How the ‘No Buy’ Trend of 2025 Is Boosting These 3 Stocks
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.